Daily News

Daily News

Study finds metformin doses of 1000-2000 mg per day associated with similar adverse events but 2000 mg/day metformin yields best glycemic control in older diabetics

Hospital & Nursing Home Daily

2019 DEC 05 (NewsRx) -- By a News Reporter-Staff News Editor at Hospital & Nursing Home Daily -- Researchers detail new data in Nutritional and Metabolic Diseases and Conditions - Type 2 Diabetes. According to news reporting out of Shanghai, People’s Republic of China, by NewsRx editors, research stated, “Gastrointestinal discomfort is the most common adverse event of metformin treatment for type 2 diabetes, especially in elderly patients. The aim of this study was to compare gastrointestinal adverse events resulting from different doses of metformin used for the treatment of elderly people with type 2 diabetes.”

Financial supporters for this research include Key Talents Program of Huadong Hospital Affiliated to Fudan University, Scientific Research Topics of Shanghai Health and Family Planning Commission.

Our news journalists obtained a quote from the research from Huadong Hospital Affiliated to Fudan University, “A total of 361 elderly patients with newly diagnosed diabetes were randomly divided into three groups: metformin 1000 mg/d (N=120), metformin 1500 mg/d (N=121) and metformin 2000 mg/d (N=120). Glycaemic control and gastrointestinal adverse events (abdominal pain, diarrhoea, nausea, vomiting, bloating and anorexia) were assessed and compared among the three groups after 12 weeks of treatment. At baseline, there was no significant difference in gastrointestinal symptoms among the three groups. After 12 weeks of treatment with metformin, the change in HbA level was -0.7%, -0.9% and -1.0% for the 1000 mg/d, 1500 mg/d and 2000 mg/d groups, respectively (p <.0001). There was no significant difference in gastrointestinal adverse events among the three groups after treatment with metformin. In total, 62 people (17.2%) could not tolerate the adverse effects of metformin, and most of them stopped treatment in the first 4 weeks. Logistic regression analysis shows that female sex (OR=2.660, 95%CI 1.692-4.183, p<.0001) and the concurrent use of organic cation transporter 1-inhibiting drugs (OR=1.874, 95%CI 1.076-3.265, p=.027) are independent risk factors for adverse events. Our data demonstrate that metformin doses of 1000 mg/d-2000 mg/d have similar adverse events but that 2000 mg/d of metformin yields the best glycaemic control in elderly people with diabetes.”

According to the news editors, the research concluded: “If elderly people can tolerate 1000 mg/d of metformin, we could gradually increase the dose to 2000 mg/d to achieve better glycaemic control.”

For more information on this research see: Comparison of gastrointestinal adverse events with different doses of metformin in the treatment of elderly people with type 2 diabetes. Journal of Clinical Pharmacy & Therapeutics, 2019;():. Journal of Clinical Pharmacy & Therapeutics can be contacted at: Blackwell Publishing Inc, 350 Main St, Malden, MA 02148, USA. (Wiley-Blackwell - http://www.wiley.com/; Journal of Clinical Pharmacy & Therapeutics - http://onlinelibrary.wiley.com/journal/10.1111/(ISSN)1365-2710)

Our news journalists report that additional information may be obtained by contacting H. Yuxin, Dept. of Endocrinology, Huadong Hospital Affiliated to Fudan University, Shanghai, People’s Republic of China. Additional authors for this research include J. Cuiping, T. Wen, Q. Jieyuzhen, T. Xiaoming, G. Qin, W. Haidong, S. Jiao and B. Zhijun.

The direct object identifier (DOI) for that additional information is: https://doi.org/10.1111/jcpt.13087. This DOI is a link to an online electronic document that is either free or for purchase, and can be your direct source for a journal article and its citation.

Publisher contact information for the Journal of Clinical Pharmacy & Therapeutics is: Blackwell Publishing Inc, 350 Main St, Malden, MA 02148, USA.

(Our reports deliver fact-based news of research and discoveries from around the world.)